Moneycontrol PRO
LAMF
LAMF

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities

    Net Sales are expected to decrease by 9.8 percent Y-o-Y (up 16.1 percent Q-o-Q) to Rs 3,984.5 crore, according to ICICI Securities.

  • Biocon shares slump 5.5% as net profit takes a dive in Q2

    While Biocon reported a dismal earnings show for Q2, the management as well as brokerage remain hopeful for a better second half of FY25. Key triggers for the stock include clarity over USFDA compliance of Biocon's Malaysia and Bengaluru facilities.

  • Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities

    Net Sales are expected to increase by 3.5 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 3,730.4 crore, according to ICICI Securities.

  • Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct

  • Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

  • Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct

  • Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak

  • Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan

  • Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct

  • Biocon confident of meeting $200-million revenue guidance target for biologics segment

  • Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan

  • Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct

  • Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak

  • Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon

  • Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

  • Optimistic about entry into generics market; hoping for better returns in H2: Biocon

  • Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak

  • Have buy rating on Glenmark Pharma: HDFC Securities

  • Biocon Q1 profit seen down 32% on weak operational performance

  • EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A

  • Biocon Q4 adjusted profit may grow 32% on strong operational performance

  • Biocon well-poised to be a frontrunner in biosimilars: MD

  • Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA

  • Biosimilars to lead growth; generics to be a small part: Biocon

  • Biocon Q2 profit seen down 55% at Rs 137cr, revenue may grow 19%

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347